Navigation Links
Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
Date:11/2/2011

CARLSBAD, Calif., Nov. 2, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it has initiated Phase 1 clinical studies for ISIS-GCGRRx and ISIS-GCCRRx, antisense drugs Isis is developing for the treatment of type 2 diabetes.  Isis will develop both ISIS-GCGRRx and ISIS-GCCRRx to treat a broad population of diabetic patients.  The unique mechanism of action of these new drugs could allow each drug to be used in combination with other therapies for type 2 diabetes.

"Type 2 diabetes is a progressive disease.  More than half of all diabetic patients cannot reach acceptable glucose control with currently available therapies.  Our goal is to develop safe, effective drugs with unique mechanisms of action that can provide significant therapeutic benefit," said B. Lynne Parshall, Chief Operating Officer, Chief Financial Officer and Secretary of Isis. "This year we have made significant progress toward this goal.  Our ISIS-GCGRRx and ISIS-GCCRRx drugs are designed to reduce the activity of two critical hormones that oppose the action of insulin and cause increased glucose levels in diabetic patients.  The initial clinical development for both of these drugs will focus on treating diabetic patients with moderate to severe diabetes who cannot achieve adequate glucose control with existing treatments.  We believe that each drug could address a significant commercial market by providing long-term disease control in such patients."

ISIS-GCGRRx targets the glucagon receptor (GCGR) to reduce the effects of glucagon, a hormone that causes glucose production in the liver.  Reducing GCGR also increases the production of active glucagon-like peptide (GLP-1), a hormone that preserves pancreatic function and enhances insulin secretion. "Glucagon plays a particularly significant role in increasing blood glucose levels
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
2. Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial Scale
3. CryoLife Initiates Enrollment in U.S. Clinical Trial for BioFoam®
4. CareFusion Initiates Class I Recall of EnVe Ventilators
5. Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
6. ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
7. Merrimack Pharmaceuticals Initiates Enrollment in a Neoadjuvant Phase 2 Study of MM-121 with Paclitaxel in HER2-negative Breast Cancer Patients
8. Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinsons Disease
9. Pharmasset Initiates QUANTUM, a Phase 2b Interferon-Free Trial of PSI-7977 and PSI-938 for All HCV Genotypes
10. Nektar Initiates Second Phase 1 Clinical Study Evaluating NKTR-181, A Novel Opioid Molecule, for Treatment of Chronic Pain
11. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... August 27, 2015 According to a new ... Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, Canvas), Usage ... 2020", published by MarketsandMarkets, the Medical Lifting Sling Market is poised ... in 2015, at a CAGR of 11.4 % from 2015 to ... ma rket data T ables and 65 ...
(Date:8/27/2015)... --  Women Grow , the fastest-growing professional networking organization for ... Cannabis World Congress & Business Exposition (CWCBExpo) in ... educational sessions. CWCBExpo in LA will take place September 16-18, ... Center in Los Angeles, CA , and ... the marijuana industry. The Women Grow tracks at ...
(Date:8/27/2015)... Aug. 27, 2015  A mere one in seven ... Allen Hamilton . A new white paper ... are impeding and disrupting manufacturers, success. The ... Improve Value In Product Development Processes provides insight ... and how it affects the product development process resulting ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4New White Paper Reveals How Manufacturers Can Improve Product Development Processes 2
... no stent thrombosis or MACE,after one year, ... 2007,/PRNewswire-FirstCall/ -- Boston Scientific Corporation today,welcomed the ... FIRST, II,and III Clinical Trials, reaffirming prior ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System and XIENCE(TM) V ...
... of Choroidal,Neovascularization (CNV) in an AMD Model, SAN ... ,the category leader in therapeutic agents against bioactive ... of human age-related macular degeneration (AMD). , The ... the,Association of Research in Vision and Ophthalmology (ARVO) ...
Cached Medicine Technology:SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 2SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus,Drug-Eluting Coronary Stent Systems 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4
(Date:8/28/2015)... Boynton Beach, FL. (PRWEB) , ... August 28, ... ... creating problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new ... Strawbridge believes that it should begin with the employer and employees getting together ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... a low cost. Personalized with practice contact information and logos, Calendars stand alone ... can also incorporate Calendars into seasonal mailings, thank you and welcome communications, and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics throughout ... go deep sea diving. The act of recreational diving exposes the body ... reasons, it is vital that all recreational and professional divers undergo regular comprehensive ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... of the top 5 millionaire dating sites . According to the listings, ... the second best in this category. , A spokesperson of Top5MillionaireDatingSites.com ...
(Date:8/28/2015)... ... , ... Inc. magazine today ranked PREVENT Life Safety No. 3660 ... private companies. The list was unveiled online at Inc.com and is the most competitive ... years, PREVENT ranks higher on the list than any other company in their industry. ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... tailor therapy regimen to individuals, experts say , , TUESDAY, ... affect the way children respond to treatment for lymphoblastic ... children suffering from this type of blood and bone ... to treatment. Now researchers think they know why. , ...
... radiation indicates need for earlier screening, study notes, , , ... female childhood cancer survivors under the age of 40 ... are not following the recommended advice to get screening ... The recommendation suggests starting screening mammograms at age 25, ...
... Ill., Jan. 27 EngagementHealth, LLC., an innovator ... launch of its comprehensive disease prevention and health ... RBNF ). Rurban Financial is a leading ... services, and bank data and item processing, headquartered ...
... point-of-use and central pharmacy automation solutionsMOUNTAIN VIEW, Calif., Jan. ... a leading provider of system solutions to acute healthcare ... by Emory Healthcare for Omnicell point-of-use and central pharmacy ... (NASDAQ: OMCL ) is a leading provider ...
... 27, 2009 Environmental Tobacco Smoke (ETS) commonly called ... account for complications during pregnancy and birth. It is ... than do whites from smoking and ETS exposure. In ... the American Journal of Preventive Medicine , researchers ...
... Jan. 27 Trust for America,s Health (TFAH) applauds ... funding to improve the health of Americans while stimulating ... "This funding is desperately needed to revitalize and ... be putting more Americans to work in programs that ...
Cached Medicine News:Health News:In Kids, Genes May Affect Leukemia Treatment 2Health News:In Kids, Genes May Affect Leukemia Treatment 3Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 2Health News:Childhood Cancer Survivors Not Getting Recommended Mammograms 3Health News:EngagementHealth(R) Launches Comprehensive Wellness Programs With Rurban Financial Corp. (Nasdaq - RBNF) 2Health News:Avoiding secondhand smoke during pregnancy 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 2Health News:Trust for America's Health Applauds Public Health Funding in Senate Stimulus Bill as Down Payment for Containing Health Care Costs 3
... and Response catheters comprise the world's ... for electrophysiology procedures. Their advanced catheter ... superior torque response with a soft, ... and French sizes, Supreme and Response ...
... Jude Medical's line of guiding introducers ... RAMP, and 2 piece steerable, all ... catheters when the varying curves and ... physician technique. St. Jude Medical guiding ...
Novus 3000 A fully-integrated and powerful 532 nm Operating Room Photocoagulator with reliable DPSS technology and simplified operation using a touch screen interface and remote control....
... provide outstanding insertion performance, with ... high kink resistance and minimal ... sheath cannula provides optimal strength ... an extra strong dilator to ...
Medicine Products: